Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males
Pakistan Journal of Pharmaceutical Sciences. 2013; 26 (3): 577-584
en Inglés
| IMEMR
| ID: emr-142620
ABSTRACT
The effect of pitavastatin and SLCO1B1 genetic background on the pharmacokinetic and pharmacodynamic properties of repaglinide was investigated. In this randomized, placebo-controlled, crossover study, twelve healthy Chinese males were administered with pitavastatin 4 mg/d or the placebo for 5 d followed by repaglinide 4 mg given orally on d 5. Plasma repaglinide and glucose levels were measured by liquid chromatography-tandem mass spectrometry [LC/MS/MS] and the glucose oxidase method, respectively. Treatment with pitavastatin significantly increased the peak plasma concentration [C[max]] of repaglinide [P=0.003] in SLCO1B1[asterisk]1b homozygotes [P=0.015] and SLCO1B1[asterisk]15 carriers [P=0.031]. Treatment with pitavastatin led to a marginal increase in the area under plasma concentration-time curve from 0 h to infinity [AUC[0][rightwards arrow][infinity]] of repaglinide [P=0.091]. There was no significant difference in pharmacokinetic parameters or hypoglycemic effects of repaglinide among SLCO1B1 genotypes in either the pitavastatin or control group. Pitavastatin increased the C[max] of the plasma concentration of repaglinide in an SLCO1B1 genotype dependent manner, but had no apparent effect on the pharmacodynamics of repaglinide in healthy volunteers. The p values for this statement were not reported
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Piperidinas
/
Glucemia
/
Carbamatos
/
Estudios Cruzados
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Área Bajo la Curva
/
Transportadores de Anión Orgánico
/
Pueblo Asiatico
/
Hipoglucemiantes
Tipo de estudio:
Ensayo Clínico Controlado
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Pak. J. Pharm. Sci.
Año:
2013
Similares
MEDLINE
...
LILACS
LIS